Actively Recruiting
Evaluation of the Impact of a Collaboration Between Hospital and Community Pharmacists at Hospital Discharge
Led by Pharmacie des Hopitaux de l'Est Lemanique · Updated on 2026-04-16
150
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to evaluate the impact of an enhanced collaboration between a hospital pharmacist and a community pharmacist during hospital discharge. For patients taking multiple medications, hospitalization often involves numerous changes to their treatment regimen. For community pharmacies, discharge prescriptions are often complex, and they sometimes lack the information that pharmacists need to deliver the treatment as safely as possible. As a result, there is a risk of medication errors, and a risk for patients. We aim to evaluate the benefits of this collaboration for adult patients admitted to the internal medicine ward of a regional hospital who are taking seven or more drugs and are being discharged to home. The main question it aims to answer is : Does the enhanced collaboration reduce the number of drug-related problems encountered by community pharmacists with discharge prescriptions ? Researchers will compare patients when a hospital pharmacist is involved during the discharge process and when he or she is not involved, which corresponds to normal care. The hospital pharmacist will not perform the intervention directly on the patient, but only with the community pharmacy. Once they agree to participate in the study, patients will only have to go to their usual community pharmacy after discharge and accept that the hospital transmits medical information to their usual pharmacy.
CONDITIONS
Official Title
Evaluation of the Impact of a Collaboration Between Hospital and Community Pharmacists at Hospital Discharge
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to the internal medicine ward for more than 48 hours
- Patients prescribed seven or more drugs at the time of screening
- Patients discharged to home
- Patients able to give informed consent as documented by signature
You will not qualify if you...
- Patient discharged to another hospital, nursing home or rehabilitation clinic
- Refusal of the community pharmacy to participate
- Inability to sign consent and follow the procedures of the study, due to language problems, psychological disorders, dementia, alterations of consciousness and lack of judgement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Riviera-Chablais, Vaud-Valais
Rennaz, Canton of Vaud, Switzerland, 1847
Actively Recruiting
Research Team
P
Paul Garin, PharmD
CONTACT
A
Anne-Laure Blanc, PharmD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here